Search

Displaying results 1911 - 1920 of 7687 in total
  1. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

  2. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

  3. Drug

    Invert sugar

    go.drugbank.com/drugs/DB09344
    Experimental

    [A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS). … It is formed by an equal amount of glucose and fructose. It differentiates from sugar cane in the rotation of the polarized light, which in the case of invert sugar it is to the left (levorotatory).

  4. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence … Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV.

    Mixtures: GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL), GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL)
  5. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.

  6. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in th...

  7. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    donor due to the risks of graft rejection, graft-versus-host disease, and other treatment-related toxic effects. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  8. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia. … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  9. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis. … D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371].

    Synonyms: D-.ALPHA.-TOCOPHEROL POLYETHYLENE GLYCOL 1000 SUCCINATE
  10. Drug

    Edrophonium

    go.drugbank.com/drugs/DB01010
    Approved

    It has also been used as an antidote to curare principles.